memantine has been researched along with Anankastic Personality in 34 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to examine the effects of memantine as an adjuvant treatment for obsessive compulsive (OC) symptoms in patients with bipolar disorder (BD) type I, manic phase." | 9.24 | Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. ( Ghanizadeh, A; Jahromi, LR; Mowla, A; Sahraian, A, 2017) |
| "There is growing evidence that memantine, a noncompetitive N-methyl-D-aspartate receptor antagonist, may be applied as an add-on in treating patients suffering from obsessive-compulsive disorders (OCD)." | 9.17 | In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). ( Afshar, H; Bajoghli, H; Brand, S; Hafezian, H; Haghighi, M; Holsboer-Trachsler, E; Jahangard, L; Mohammad-Beigi, H; Rahimi, A, 2013) |
| "There is a growing body of evidence for the efficacy of memantine augmentation in patients with obsessive-compulsive disorder (OCD)." | 9.17 | Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. ( Akhondzadeh, S; Ashrafi, M; Askari, N; Entezari, N; Ghaleiha, A; Hajiaghaee, R; Modabbernia, A; Najand, B; Tabrizi, M, 2013) |
| "Chronic quinpirole (QNP) sensitization is an established animal model relevant to obsessive-compulsive disorder (OCD) that has been previously shown to induce several OCD-like behavioral patterns, such as compulsive-like checking and increased locomotion." | 7.91 | No effect of riluzole and memantine on learning deficit following quinpirole sensitization - An animal model of obsessive-compulsive disorder. ( Brozka, H; Janikova, M; Radostova, D; Stuchlik, A; Svoboda, J, 2019) |
| "Memantine has an acceptable safety and tolerability in patients with OCD and might have a positive effect on their executive function." | 7.11 | Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial. ( Askari, S; Mokhtari, S; Shalbafan, M; Shariat, SV; Shariati, B; Yarahmadi, M, 2022) |
| "Memantine is an effective and well-tolerated augmentation in severe OCD patients refractory to SRI monotherapy." | 6.87 | Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial. ( Eslami, K; Javadi, M; Kouti, L; Modarresi, A; Razooghi, S; Sayyah, M, 2018) |
| "Memantine was well tolerated, and there were no serious adverse effects." | 6.74 | Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. ( Bystritsky, A; Feusner, JD; Kerwin, L; Saxena, S, 2009) |
| "Catatonia is a syndrome with protean manifestations and multiple aetiologies." | 5.37 | Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery. ( Jean-Baptiste, M; Mukai, Y; Two, A, 2011) |
| "Memantine is an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist." | 5.33 | Memantine augmentation for refractory obsessive-compulsive disorder. ( Biondi, M; Pasquini, M, 2006) |
| "The aim of this study is to examine the effects of memantine as an adjuvant treatment for obsessive compulsive (OC) symptoms in patients with bipolar disorder (BD) type I, manic phase." | 5.24 | Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. ( Ghanizadeh, A; Jahromi, LR; Mowla, A; Sahraian, A, 2017) |
| "This 12-week study has an add-on, randomised, double-blind, placebo-controlled design of treatment with memantine, including an up-titration phase (forced flexible dose design, 5-15 mg/day), in patients aged 6-17 years and 9 months with obsessive-compulsive disorder or autism spectrum disorder." | 5.22 | Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial. ( Banaschewski, T; Buitelaar, JK; Dijkhuizen, RM; Dittmann, RW; Franke, B; Häge, A; Lythgoe, DJ; Mechler, K; Williams, SC, 2016) |
| "There is growing evidence that memantine, a noncompetitive N-methyl-D-aspartate receptor antagonist, may be applied as an add-on in treating patients suffering from obsessive-compulsive disorders (OCD)." | 5.17 | In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). ( Afshar, H; Bajoghli, H; Brand, S; Hafezian, H; Haghighi, M; Holsboer-Trachsler, E; Jahangard, L; Mohammad-Beigi, H; Rahimi, A, 2013) |
| "There is a growing body of evidence for the efficacy of memantine augmentation in patients with obsessive-compulsive disorder (OCD)." | 5.17 | Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. ( Akhondzadeh, S; Ashrafi, M; Askari, N; Entezari, N; Ghaleiha, A; Hajiaghaee, R; Modabbernia, A; Najand, B; Tabrizi, M, 2013) |
| "Chronic quinpirole (QNP) sensitization is an established animal model relevant to obsessive-compulsive disorder (OCD) that has been previously shown to induce several OCD-like behavioral patterns, such as compulsive-like checking and increased locomotion." | 3.91 | No effect of riluzole and memantine on learning deficit following quinpirole sensitization - An animal model of obsessive-compulsive disorder. ( Brozka, H; Janikova, M; Radostova, D; Stuchlik, A; Svoboda, J, 2019) |
| "Memantine has an acceptable safety and tolerability in patients with OCD and might have a positive effect on their executive function." | 3.11 | Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial. ( Askari, S; Mokhtari, S; Shalbafan, M; Shariat, SV; Shariati, B; Yarahmadi, M, 2022) |
| "Memantine was found to be most effective augmentation agent for SRIs in OCD, followed by lamotrigine, ondansetron and granisetron with moderate certainty of evidence." | 3.01 | Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis. ( Maiti, R; Mishra, A; Mishra, BR; Srinivasan, A, 2023) |
| "Memantine is an effective and well-tolerated augmentation in severe OCD patients refractory to SRI monotherapy." | 2.87 | Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial. ( Eslami, K; Javadi, M; Kouti, L; Modarresi, A; Razooghi, S; Sayyah, M, 2018) |
| "Memantine was well tolerated, and there were no serious adverse effects." | 2.74 | Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. ( Bystritsky, A; Feusner, JD; Kerwin, L; Saxena, S, 2009) |
| "Memantine treatment did not affect compulsive checking nor frontostriatal structural and functional connectivity in the quinpirole-induced adolescent rat model." | 1.72 | Memantine treatment does not affect compulsive behavior or frontostriatal connectivity in an adolescent rat model for quinpirole-induced compulsive checking behavior. ( Blezer, ELA; Buitelaar, JK; Dijkhuizen, RM; Glennon, JC; Otte, WM; Smeele, CE; Straathof, M; van der Toorn, A; van Heijningen, C, 2022) |
| "Memantine is a N-methyl-D-aspartate (NMDA) receptor antagonist currently used for moderate-to-severe Alzheimer's disease." | 1.56 | Memantine misuse and social networks: A content analysis of Internet self-reports. ( Michel, B; Natter, J, 2020) |
| "Memantine treatment was associated with diminished impulsive buying and improvements on cognitive tasks of impulsivity." | 1.38 | Open-label pilot study of memantine in the treatment of compulsive buying. ( Grant, JE; Kim, SW; Mooney, M; O'Brien, R; Odlaug, BL, 2012) |
| "Catatonia is a syndrome with protean manifestations and multiple aetiologies." | 1.37 | Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery. ( Jean-Baptiste, M; Mukai, Y; Two, A, 2011) |
| "Memantine is an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist." | 1.33 | Memantine augmentation for refractory obsessive-compulsive disorder. ( Biondi, M; Pasquini, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (23.53) | 29.6817 |
| 2010's | 20 (58.82) | 24.3611 |
| 2020's | 6 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Askari, S | 1 |
| Mokhtari, S | 1 |
| Shariat, SV | 1 |
| Shariati, B | 1 |
| Yarahmadi, M | 1 |
| Shalbafan, M | 1 |
| Straathof, M | 1 |
| Blezer, ELA | 1 |
| Smeele, CE | 1 |
| van Heijningen, C | 1 |
| van der Toorn, A | 1 |
| Buitelaar, JK | 2 |
| Glennon, JC | 2 |
| Otte, WM | 1 |
| Dijkhuizen, RM | 3 |
| Maiti, R | 1 |
| Mishra, A | 1 |
| Srinivasan, A | 1 |
| Mishra, BR | 1 |
| Modarresi, A | 2 |
| Chaibakhsh, S | 1 |
| Koulaeinejad, N | 1 |
| Koupaei, SR | 1 |
| Andrade, C | 1 |
| Li, H | 1 |
| Xing, M | 1 |
| Zhang, C | 1 |
| Natter, J | 1 |
| Michel, B | 1 |
| Janikova, M | 2 |
| Mainerova, K | 1 |
| Vojtechova, I | 1 |
| Petrasek, T | 1 |
| Svoboda, J | 2 |
| Stuchlik, A | 2 |
| M Koran, L | 1 |
| Aboujaoude, E | 2 |
| Mechler, K | 2 |
| Häge, A | 2 |
| Schweinfurth, N | 1 |
| Murphy, D | 1 |
| Durston, S | 1 |
| Williams, S | 1 |
| K Buitelaar, J | 1 |
| Banaschewski, T | 2 |
| Dittmann, RW | 2 |
| Tactics Consortium, T | 1 |
| Sayyah, M | 1 |
| Razooghi, S | 1 |
| Eslami, K | 1 |
| Javadi, M | 1 |
| Kouti, L | 1 |
| Kishi, T | 1 |
| Matsuda, Y | 1 |
| Iwata, N | 1 |
| Farnia, V | 1 |
| Gharehbaghi, H | 1 |
| Alikhani, M | 1 |
| Almasi, A | 1 |
| Golshani, S | 1 |
| Tatari, F | 1 |
| Davarinejad, O | 1 |
| Salemi, S | 1 |
| Sadeghi Bahmani, D | 1 |
| Holsboer-Trachsler, E | 2 |
| Brand, S | 2 |
| Brozka, H | 1 |
| Radostova, D | 1 |
| Haghighi, M | 1 |
| Jahangard, L | 1 |
| Mohammad-Beigi, H | 1 |
| Bajoghli, H | 1 |
| Hafezian, H | 1 |
| Rahimi, A | 1 |
| Afshar, H | 1 |
| Pekrul, SR | 1 |
| Fitzgerald, KD | 1 |
| Franke, B | 1 |
| Lythgoe, DJ | 1 |
| Williams, SC | 1 |
| Rodriguez, CI | 1 |
| Levinson, A | 1 |
| Zwerling, J | 1 |
| Vermes, D | 1 |
| Simpson, HB | 1 |
| Sahraian, A | 1 |
| Jahromi, LR | 1 |
| Ghanizadeh, A | 1 |
| Mowla, A | 1 |
| Barry, JJ | 1 |
| Gamel, N | 1 |
| Hezel, DM | 2 |
| Beattie, K | 1 |
| Stewart, SE | 2 |
| Feusner, JD | 1 |
| Kerwin, L | 1 |
| Saxena, S | 1 |
| Bystritsky, A | 1 |
| Wald, R | 1 |
| Dodman, N | 1 |
| Shuster, L | 2 |
| Jenike, EA | 1 |
| Stack, DE | 1 |
| Dodman, NH | 1 |
| Jenike, MA | 1 |
| Holden, C | 1 |
| Travis, J | 1 |
| Bernhardt, EB | 1 |
| Walsh, KH | 1 |
| Posey, DJ | 1 |
| McDougle, CJ | 1 |
| Chopra, MP | 1 |
| Trevino, KM | 1 |
| Kowall, NW | 1 |
| Grant, JE | 1 |
| Odlaug, BL | 1 |
| Mooney, M | 1 |
| O'Brien, R | 1 |
| Kim, SW | 1 |
| Mukai, Y | 1 |
| Two, A | 1 |
| Jean-Baptiste, M | 1 |
| Ghaleiha, A | 1 |
| Entezari, N | 1 |
| Modabbernia, A | 1 |
| Najand, B | 1 |
| Askari, N | 1 |
| Tabrizi, M | 1 |
| Ashrafi, M | 1 |
| Hajiaghaee, R | 1 |
| Akhondzadeh, S | 1 |
| Poyurovsky, M | 1 |
| Weizman, R | 1 |
| Weizman, A | 1 |
| Koran, L | 1 |
| Pasquini, M | 1 |
| Biondi, M | 1 |
| Zdanys, K | 1 |
| Tampi, RR | 1 |
| Egashira, N | 1 |
| Okuno, R | 1 |
| Harada, S | 1 |
| Matsushita, M | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Nishimura, R | 1 |
| Oishi, R | 1 |
| Fujiwara, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Memantine for Refractory OCD Patients: a Pragmatic Double Blind, Randomized, Parallel Group, Placebo Controlled, Monocentric Trial[NCT05015595] | Phase 3 | 20 participants (Anticipated) | Interventional | 2021-09-01 | Not yet recruiting | ||
| Open -Label Trial on the Effects of Memantine in Adults With Obsessive-Compulsive Disorder After a Single Ketamine Infusion[NCT00956085] | Phase 2 | 12 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder[NCT00264238] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Differential Efficacy of Memantine for Obsessive-compulsive Disorder vs. Generalized Anxiety Disorder: an Open-label Trial[NCT00674219] | Phase 3 | 17 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Augment in Treatment-resistent Obsessive-compulsive Disorder: an Open-label Trial[NCT00590642] | 30 participants (Anticipated) | Observational | 2006-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients given YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response was defined as at least a 35% reduction on the YBOCS. (NCT00956085)
Timeframe: Baseline and 6 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Memantine | 4 |
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Each item is rated on a scale of 0 (no symptoms) to 6 (extreme symptoms) and items are summed. The overall score ranges from 0 to 60. Higher MADRS score indicates more severe depression. (NCT00264238)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Mean at baseline | Mean at end of treatment | |
| Non-Responders: Memantine Open Label | 14.9 | 14.6 |
| Responders: Memantine Open Label | 11.8 | 5.0 |
The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is designed to rate the severity and type of symptoms in patients with obsessive compulsive disorder. In general, the items depend on the patient's report; however, the final rating is based on the clinical judgement of the interviewer. The Y-BOCS is designed to rate symptom severity, not to establish a diagnosis.The scale consists of 10 items summed to determine the level of symptom severity. The total score ranges from 0 to 40 with higher scores indicating greater symptom severity (NCT00264238)
Timeframe: Baseline and 12 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| At baseline | At end of treatment | |
| Non-Responders: Memantine Open Label | 30 | 28.8 |
| Responders: Memantine Open Label | 23.8 | 13.0 |
The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CY-BOCS Baseline | CY-BOCS Day 14 | |
| Ketamine Treatment Group | 29.00 | 26.20 |
The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CGI-S Baseline | CGI-S Day 14 | |
| Ketamine Treatment Group | 5.80 | 5.00 |
"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| OCD-VAS Baseline | OCD-VAS Day 14 | |
| Ketamine Treatment Group | 5.00 | 5.00 |
"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Y-BOCCS Baseline | Y-BOCCS Day 14 | |
| Ketamine Treatment Group | 18.25 | 16.50 |
"Participants in the OCD group were rated using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), a standard measure of obsessive-compulsive disorder (OCD) severity in pharmacotherapy studies. It is administered by a trained rater. It comprises 10 items assessing OCD symptoms (e.g. time spent, degree of control, severity). Each item is scored on a scale from 0 (not present) to 4 (severe) [total score range = 0-40] over the previous week. The higher the number on the Y-BOCS, the more severe the symptoms.~Participants in the GAD group were rated using the Hamilton Anxiety Rating Scale (HARS), a standard measure of anxiety severity in pharmacotherapy studies. It is administered by a trained rater. It comprises 14 items assessing anxiety symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe." (NCT00674219)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| 12 weeks | Baseline | |
| GAD Group | 18.86 | 24.3 |
| OCD Group | 16.4 | 27.6 |
6 reviews available for memantine and Anankastic Personality
| Article | Year |
|---|---|
Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis.
Topics: Bayes Theorem; Drug Therapy, Combination; Granisetron; Humans; Lamotrigine; Memantine; Network Meta- | 2023 |
A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder.
Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Hu | 2019 |
Augmentation With Memantine in Obsessive-Compulsive Disorder.
Topics: Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Therapy, Combination; Humans; Memantin | 2019 |
Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research.
Topics: Caffeine; Cognitive Behavioral Therapy; Combined Modality Therapy; Humans; Ketamine; Memantine; Obse | 2018 |
Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry: a Systematic Review of the Literature.
Topics: Acetylcysteine; Adolescent; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; | 2018 |
A systematic review of off-label uses of memantine for psychiatric disorders.
Topics: Anxiety; Bipolar Disorder; Bulimia Nervosa; Child; Child Development Disorders, Pervasive; Depressio | 2008 |
9 trials available for memantine and Anankastic Personality
| Article | Year |
|---|---|
Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
Topics: Double-Blind Method; Drug Therapy, Combination; Executive Function; Humans; Iran; Memantine; Obsessi | 2022 |
Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial.
Topics: Adolescent; Adult; Cohort Studies; Dopamine Agents; Double-Blind Method; Drug Synergism; Female; Hum | 2018 |
Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: Double-blind, randomized, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Dopamine Agents; Double-Blind Method; Female; Fluoxetine; Gabapentin; Humans | 2018 |
In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).
Topics: Adult; Clomipramine; Double-Blind Method; Drug Therapy, Combination; Excitatory Amino Acid Antagonis | 2013 |
Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
Topics: Adolescent; Adolescent Behavior; Autism Spectrum Disorder; Brain; Child; Child Behavior; Clinical Pr | 2016 |
Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion.
Topics: Administration, Intravenous; Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Subs | 2016 |
Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Topics: Adjuvants, Pharmaceutic; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Dis | 2017 |
Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
Topics: Adult; Anxiety Disorders; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Middle | 2009 |
Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Antiparkinson Age | 2013 |
19 other studies available for memantine and Anankastic Personality
| Article | Year |
|---|---|
Memantine treatment does not affect compulsive behavior or frontostriatal connectivity in an adolescent rat model for quinpirole-induced compulsive checking behavior.
Topics: Animals; Compulsive Behavior; Disease Models, Animal; Dopamine Agonists; Memantine; Obsessive-Compul | 2022 |
Antipsychotics-associated obsessive-compulsive symptoms: individualized treatments and clinical benefits of memantine: a case report.
Topics: Adult; Antipsychotic Agents; Humans; Male; Memantine; Obsessive-Compulsive Disorder; Schizophrenia; | 2020 |
Memantine misuse and social networks: A content analysis of Internet self-reports.
Topics: Anxiety; Attention Deficit Disorder with Hyperactivity; Depression; Humans; Internet; Memantine; Obs | 2020 |
Memantine and Riluzole Exacerbate, Rather Than Ameliorate Behavioral Deficits Induced by 8-OH-DPAT Sensitization in a Spatial Task.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Disease Models, Animal; Male; Mem | 2021 |
Combination Therapy of Serotonin Reuptake Inhibitors and Memantine for Obsessive- Compulsive Disorder: A Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
Topics: Adult; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Meta | 2018 |
No effect of riluzole and memantine on learning deficit following quinpirole sensitization - An animal model of obsessive-compulsive disorder.
Topics: Animals; Behavior, Animal; Cognition; Disease Models, Animal; Dopamine Agonists; Excitatory Amino Ac | 2019 |
Memantine Augmentation in a Down's Syndrome Adolescent with Treatment- Resistant Obsessive-Compulsive Disorder.
Topics: Adolescent; Down Syndrome; Drug Synergism; Excitatory Amino Acid Antagonists; Fluoxetine; Humans; Ma | 2015 |
Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
Topics: Adult; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Excitatory Amino Ac | 2009 |
Memantine as an augmenting agent for severe pediatric OCD.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Dopamine Agonists; | 2009 |
The combined effects of memantine and fluoxetine on an animal model of obsessive compulsive disorder.
Topics: Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Fluoxetine; Male; Memant | 2009 |
A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Drug Administration Schedule; Dr | 2010 |
Profile: Nicholas Dodman. Can dogs behaving badly suggest a new way to treat OCD?
Topics: Animals; Behavior, Animal; Cadherins; Compulsive Behavior; Disease Models, Animal; Dog Diseases; Dog | 2010 |
Memantine for comorbid obsessive-compulsive disorder and Asperger disorder suggests a link in glutamatergic dysregulation.
Topics: Adolescent; Asperger Syndrome; Excitatory Amino Acid Antagonists; Humans; Male; Memantine; Obsessive | 2011 |
Memantine for posttraumatic stress disorder in an older veteran.
Topics: Antipsychotic Agents; Benzodiazepines; Excitatory Amino Acid Antagonists; Female; Humans; Male; Mema | 2011 |
Open-label pilot study of memantine in the treatment of compulsive buying.
Topics: Adult; Compulsive Behavior; Dose-Response Relationship, Drug; Female; Humans; Male; Memantine; Middl | 2012 |
Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Chronic Disease; Combined Modality Therapy; Do | 2011 |
Memantine for treatment-resistant OCD.
Topics: Adult; Clomipramine; Dopamine Antagonists; Drug Therapy, Combination; Excitatory Amino Acid Antagoni | 2005 |
Memantine augmentation for refractory obsessive-compulsive disorder.
Topics: Adult; Drug Resistance; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Humans | 2006 |
Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder.
Topics: Acoustic Stimulation; Amantadine; Animals; Behavior, Animal; Dizocilpine Maleate; Excitatory Amino A | 2008 |